Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
80.56
+1.42 (+1.79%)
4:28:07 PM EDT: $80.70 +0.14 (+0.17%)
Products, Regulatory

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery

Published: 12/17/2021 14:46 GMT
Merck & Co Inc (MRK) - Merck Receives Positive Eu Chmp Opinion for Keytruda® (pembrolizumab) As Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery.
Merck & Co Inc - Recommendation Based on Significant Disease-free Survival Benefit Demonstrated With Keytruda Versus Placebo in Phase 3 Keynote-564 Trial.
Merck & Co Inc - Positive Opinion is Based on Results From Pivotal Phase 3 Keynote-564 Trial.
Merck & Co - Chmp's Recommendation Will Now Be Reviewed by European Commission for Marketing Authorization in Eu, Final Decision Expected in Q1 2022.